EKTA.B

47.86

-0.17%↓

EKTA.B

47.86

-0.17%↓

EKTA.B

47.86

-0.17%↓

EKTA.B

47.86

-0.17%↓

EKTA.B

47.86

-0.17%↓

Search

Camurus AB

Closed

564.5 0.18

Overview

Share price change

24h

Current

Min

559

Max

565

Key metrics

By Trading Economics

Income

24M

166M

Sales

74M

553M

P/E

Sector Avg

78.273

59.668

EPS

2.45

Profit margin

30.023

Employees

256

EBITDA

21M

190M

Market Stats

By TradingEconomics

Market Cap

33B

Previous open

564.32

Previous close

564.5

Camurus AB Chart

Past performance is not a reliable indicator of future results.

Related News

19 Apr 2025, 01:45 UTC

Earnings

Preview -- Barron's

18 Apr 2025, 15:57 UTC

Major Market Movers

Eli Lilly CEO Ricks Warns Against Unintentionally Raising Prices as Weight-Loss Pill Nears Market Launch

20 Apr 2025, 22:32 UTC

Top News

Stocks Poised for Lower Open -- Barrons.com

20 Apr 2025, 18:43 UTC

Top News

Chicago Fed's Goolsbee Has a Warning About Independence -- Barrons.com

20 Apr 2025, 18:00 UTC

Top News

Tesla, Alphabet, Verizon, Chipotle, IBM, Boeing, and Many More Stocks to Watch This Week -- Barrons.com

20 Apr 2025, 13:00 UTC

Top News

Airbus Promised a Green Aircraft. That Bet Is Now Unraveling. -- WSJ

20 Apr 2025, 06:00 UTC

Top News

Foreign Stocks Are Beating the U.S. Market. Here's How Much You Should Have in Your Portfolio. -- Barrons.com

20 Apr 2025, 03:00 UTC

Top News

Putin's War Economy Can't Escape Trump's Trade Blitz -- WSJ

20 Apr 2025, 02:00 UTC

Top News

Who Will Pay the Price for Trump's Economic Goals? -- WSJ

19 Apr 2025, 02:00 UTC

Top News

Tomatoes Become One of the First Everyday Casualties of Trade War -- WSJ

19 Apr 2025, 02:00 UTC

Top News

Beijing Stokes Patriotic Fervor and Blames U.S. for Trade War -- WSJ

18 Apr 2025, 20:42 UTC

Acquisitions, Mergers, Takeovers

What Bill Ackman Sees in Hertz and Why He's Betting Big on the Rental-Car Company -- Barrons.com

18 Apr 2025, 20:32 UTC

Top News

Trump to Replace Acting IRS Commissioner -- 2nd Update

18 Apr 2025, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

18 Apr 2025, 19:52 UTC

Market Talk

Correction to Aluminum Fee Rising Slower Than Forecast Article

18 Apr 2025, 19:40 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

18 Apr 2025, 19:40 UTC

Market Talk

Aluminum Fee Rising Slower Than Forecast From Tariff -- Market Talk

18 Apr 2025, 18:51 UTC

Earnings

Netflix Has Made Several Risky Bets. Earnings Show They've Paid Off. -- Barrons.com

18 Apr 2025, 18:40 UTC

Acquisitions, Mergers, Takeovers

What Bill Ackman Sees in Hertz and Why He's Betting Big on the Rental-Car Company -- Barrons.com

18 Apr 2025, 18:29 UTC

Market Talk

Shorter Duration Seen as Way to Shield Portfolio From Political Turbulence -- Market Talk

18 Apr 2025, 18:21 UTC

Top News

Ford Halts Shipments of F-150s and Other Models to China -- WSJ

18 Apr 2025, 17:31 UTC

Top News

Trump to Replace Acting IRS Commissioner -- WSJ

18 Apr 2025, 17:24 UTC

Acquisitions, Mergers, Takeovers

Capital One's Discover Takeover Gets the Green Light. The Two Will Create the 6th-Largest U.S. Bank. -- Barrons.com

18 Apr 2025, 17:22 UTC

Acquisitions, Mergers, Takeovers

Capital One's $35 Billion Discover Takeover Clears Final Approvals -- Barrons.com

18 Apr 2025, 16:00 UTC

Top News

Trump's Trade War Threatens One of America's Top Energy Exports -- WSJ

18 Apr 2025, 15:53 UTC

Top News
Acquisitions, Mergers, Takeovers

Bill Ackman Teases Prospect of Uber, Hertz Partnership -- Update

18 Apr 2025, 15:46 UTC

Earnings

Tech's Problems in China Are Getting Worse. These Companies Are Most at Risk. -- Barrons.com

18 Apr 2025, 15:10 UTC

Market Talk
Earnings

Netflix Momentum Likely To Continue Thanks To Growing Subscriber Base -- Market Talk

18 Apr 2025, 14:46 UTC

Earnings

Tech Earnings Have Good News for Chip Stocks, So Far. And 1 Warning. -- Barrons.com

18 Apr 2025, 14:24 UTC

Market Talk
Earnings

Netflix Still Has Room to Add Subscribers -- Market Talk

Peer Comparison

Price change

Camurus AB Forecast

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Camurus AB

Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain and Brixadi to treat opioid use disorder. Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; and CAM2047 that is in phase 1 clinical trial for the treatment of chemotherapy-induced nausea and vomiting. It has strategic partnerships with Braeburn Pharmaceuticals to develop CAM2038 for the treatment of opioid use disorder; and Rhythm Pharmaceuticals Inc. to develop CAM4072 for the treatment of a range of rare genetic disorders of obesity, as well as licensing agreement with Solasia Pharma. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.